Molnupiravir and Nirmatelvir/Ritonavir in the Treatment of Patients With Systemic Autoimmune Rheumatic Disease With SARS-CoV-2.

SARS-CoV-2 has certainly been at the forefront of medical discussion and research for the past 3 years. While many are adjusting back to "normal," thanks to the rapid advancements in prevention and treatment, high-risk groups, such as adults with systemic autoimmune rheumatic diseases (SARDs), still require careful monitoring and care.